US$0.98 (vs US$1.16 in 2Q 2023)
Utah Medical Products (NASDAQ:UTMD) Second Quarter 2024 Results
Key Financial Results
-
Revenue: US$10.4m (down 19% from 2Q 2023).
-
Net income: US$3.45m (down 18% from 2Q 2023).
-
Profit margin: 33% (in line with 2Q 2023).
-
EPS: US$0.98 (down from US$1.16 in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Utah Medical Products’ share price is broadly unchanged from a week ago.
Balance Sheet Analysis
While earnings are important, another area to consider is the balance sheet. See our latest analysis on Utah Medical Products’ balance sheet health.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]
